Cancer Research News 16 October 2025

Tiny Biotech INTENSITY THERAPEUTICS Stock Skyrockets on Cancer Therapy Breakthrough – Experts See Big Upside

Stock Rally on Novel Cancer Data Intensity Therapeutics (NASDAQ: INTS) has been one of the market’s biggest movers. On Oct. 30, 2025 its stock was around $0.27 per share investing.com – an 84% drop YTD but up nearly 200% intraday on

30 October 2025

Ernexa Therapeutics (ERNA) Skyrockets on Cancer Therapy Deal – Will Rally Last?

ERNA Stock Soars on Cell Therapy Breakthrough Ernexa Therapeutics Inc. – a small Cambridge, MA biotech formerly known as Eterna Therapeutics – saw its stock skyrocket on October 29 after unveiling a major collaboration to advance its cutting-edge cancer therapy.

29 October 2025

Biotech · Cancer Research · Investment News · NASDAQ:ERNA · Pharmaceuticals · Stock Market

Theriva Biologics (TOVX) Stock Soars 92% on Oncolytic Virus Trial News – Can the Rally Last?

Theriva Biologics (TOVX) Stock Surges on Cancer Trial Breakthrough – What’s Next?

Theriva’s Stock Swing: In mid-October, Theriva’s Nasdaq-traded shares spiked on news of clinical success. On Oct. 15 the stock jumped from roughly $0.44 to $0.84 intraday ts2.tech, an increase of about 92%. This surge coincided with reports that VCN-01 had

24 October 2025

Biotech · Cancer Research · Clinical Trials · Investing · NASDAQ:TOVX · Stock Market

Inhibrx Biosciences Stock Soars on Breakthrough Cancer Trial News

Breakthrough Trial Results in Rare Bone Cancer Inhibrx’s lead drug, ozekibart, achieved a landmark win in its ChonDRAgon trial for advanced conventional chondrosarcoma. This rare bone cancer has no approved systemic therapies, so the positive data are significant. According to

24 October 2025

Biotechnology · Cancer Research · Medical News · NASDAQ:INBX · Pharma Industry · Stock Market

Celcuity Stock Skyrockets 40% to Record High on ‘Practice-Changing’ Cancer Trial Results

Stock Soars on Positive Trial News Celcuity’s stock price skyrocketed on October 20, 2025 after the Minneapolis-based biotech reported game-changing clinical trial results. Shares jumped from around $52 to as high as $78–$81 intraday marketbeat.com, an approximately 40–50% single-day leap,

20 October 2025

Biotechnology · Cancer Research · Clinical Trials · Investment News · NASDAQ:CELC · Stock Market

Sellas Life Sciences (SLS) Stock Skyrockets: BlackRock’s 5% Bet and Breakthrough Cancer Data Ignite Rally

Sellas Life Sciences (NASDAQ: SLS) stock has surged roughly 100% year-to-date, closing around $2.14 on Oct. 17, 2025 ts2.tech ts2.tech (versus a 52-week low of $0.77). In after-hours trading on Oct. 17 it spiked another +38%, briefly touching a new

20 October 2025

Biotechnology · Cancer Research · Financial Analysis · Investment News · NASDAQ:SLS · Stock Market

Summit Therapeutics (SMMT) Skyrockets on Cancer Breakthrough – Key Facts & Outlook

SMMT Stock’s Wild Ride in 2025 Summit Therapeutics’ share price has been on a roller-coaster ride this year. After a steady climb through late summer, SMMT spiked above $25 intraday in mid-October, then pulled back to end last week just

20 October 2025

Biotech · Cancer Research · Investment News · Medical Breakthroughs · NASDAQ:SMMT · Stock Market

Summit Therapeutics (SMMT) Stock Soars on Cancer Breakthrough – Can the Biotech’s Rally Hold?

What to Know Before Markets Open on October 20, 2025 SMMT’s Wild Stock Ride in 2025 Summit Therapeutics’ share price has experienced extreme swings this year. After a steady climb through late summer, SMMT spiked to an intraday high above

19 October 2025

Biotech · Cancer Research · Investing · Medical News · NASDAQ:SMMT · Stock Market

GRAIL (GRAL) Stock Skyrockets on Samsung’s $110M Bet and Cancer-Screening Breakthrough

GRAIL’s logo at company headquarters. The Menlo Park biotech specializes in blood-based early cancer screening through its Galleri test news.samsung.com tradingview.com. GRAIL, Inc. is focused on early cancer detection – its mission is “to detect cancer early when it can

18 October 2025

Biotechnology · Cancer Research · Healthcare Innovation · Investment News · NASDAQ:GRAL · Stock Market

Biotech Breakthrough: GRAIL (GRAL) Stock Surges on New Cancer-Detection Data

GRAIL (GRAL) Rockets to Record High on Samsung Mega-Deal and Cancer Test Breakthrough

Samsung Partnership Sparks Stock Surge GRAIL, Inc. (NASDAQ: GRAL) shares soared to record highs this week after the company announced a strategic collaboration with Samsung. On October 16, GRAIL revealed a binding agreement in which Samsung C&T and Samsung Electronics

17 October 2025

Biotechnology · Business News · Cancer Research · Medical Innovations · NASDAQ:GRAL · Stock Market

GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

Strategic Samsung Partnership GRAIL’s shares surged after it announced a deal on Oct. 16 to partner with Samsung in Asia. The binding Letter of Intent involves Samsung C&T and Samsung Electronics investing $110 million in GRAIL at $70.05 per share, with

16 October 2025

Biotechnology · Cancer Research · Health News · NASDAQ:GRAL · Partnerships · Stock Market

Theriva Biologics Stock Skyrockets 92% on Cancer Trial Breakthrough – What’s Next for TOVX?

Recent Clinical Developments and Pipeline Updates Theriva Biologics – a Rockville, MD-based clinical-stage biotech – has made headlines with promising cancer trial results. On October 13, 2025, the company announced that expanded data from its VIRAGE Phase 2b trial in

16 October 2025

Biotech News · Cancer Research · Investment Insights · Pharma Updates · Stock Market

Cancer Research News 16 October 2025 - 30 October 2025